Diagnostic companies aim to disrupt medical industry
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Wilkinson to be new Inogen CEO as Huggenberger retires
Goleta-based respiratory product maker Inogen announced President and Chief Operating Officer Scott Wilkinson will take over as CEO of the company March 1, 2017, replacing retiring CEO Raymond Huggenberger. Wilkinson will join Huggenberger and new board member Scott Beardsley, a senior partner at San Francisco-based Novo Ventures, on the company’s board of directors, the Dec. Read More →
Startup’s app users get health advice based on genetics
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Tri-county companies self-insure employee health care coverage
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
UCLA Health expanding in Ventura County
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s Humira biosimilar delayed, Enbrel approved
Amgen’s Humira biosimilar Amjevita will be delayed at least through 2017 due to litigation by competitor AbbVie. The maker of Humira filed a patent infringement claim against Amgen on Aug. 4, alleging that the drug also violates the Biosimilar Price Competition and Innovation Act. Amgen was approved to market its biosimilar Sept. 23 by the Read More →
Sientra loses $10 million in third quarter
Sientra reported a net loss of $10 million for the third quarter of 2016, ended Sept. 30, and announced the acquisition of a new line of products. Sales for the Goleta-based breast implant manufacturer fell from $9.9 million in the third quarter of 2015 to $6.5 million this quarter, while operating expenses rose 15.3 percent. Read More →
